DB:UXI3

Stock Analysis Report

Executive Summary

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has Cyclacel Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: UXI3's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.9%

UXI3

-1.8%

DE Biotechs

0.1%

DE Market


1 Year Return

-6.6%

UXI3

7.2%

DE Biotechs

14.1%

DE Market

Return vs Industry: UXI3 underperformed the German Biotechs industry which returned 6.8% over the past year.

Return vs Market: UXI3 underperformed the German Market which returned 15.1% over the past year.


Shareholder returns

UXI3IndustryMarket
7 Day3.9%-1.8%0.1%
30 Day-5.6%-2.9%0.2%
90 Day75.4%5.8%3.3%
1 Year-6.6%-6.6%7.5%7.2%17.6%14.1%
3 Year-86.6%-86.6%42.8%41.2%14.8%4.8%
5 Year-91.3%-91.3%11.6%9.3%22.2%5.4%

Price Volatility Vs. Market

How volatile is Cyclacel Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cyclacel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.89x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate UXI3's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate UXI3's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: UXI3 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: UXI3 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UXI3's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: UXI3 is good value based on its PB Ratio (0.9x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Cyclacel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

52.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: UXI3 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: UXI3 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: UXI3 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: UXI3 is forecast to have no revenue next year.

High Growth Revenue: UXI3 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if UXI3's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cyclacel Pharmaceuticals performed over the past 5 years?

16.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: UXI3 is currently unprofitable.

Growing Profit Margin: UXI3 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: UXI3 is unprofitable, but has reduced losses over the past 5 years at a rate of 16.4% per year.

Accelerating Growth: Unable to compare UXI3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UXI3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: UXI3 has a negative Return on Equity (-54.45%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cyclacel Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: UXI3's short term assets ($15.8M) exceed its short term liabilities ($2.1M).

Long Term Liabilities: UXI3's short term assets ($15.8M) exceed its long term liabilities ($1.2M).


Debt to Equity History and Analysis

Debt Level: UXI3 is debt free.

Reducing Debt: UXI3 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: UXI3 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if UXI3's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: UXI3 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: UXI3 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 14% each year.


Next Steps

Dividend

What is Cyclacel Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate UXI3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate UXI3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UXI3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UXI3's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UXI3's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

13.9yrs

Average board tenure


CEO

Spiro Rombotis (60yo)

22.5yrs

Tenure

US$752,824

Compensation

Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Group Plc) since August 1997 and has been its Founding Chief Executive Officer since joining in August 1997 ...


CEO Compensation Analysis

Compensation vs Market: Spiro's total compensation ($USD752.82K) is above average for companies of similar size in the German market ($USD412.06K).

Compensation vs Earnings: Spiro's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Spiro Rombotis
President22.5yrsUS$752.82k1.33% $150.3k
Paul McBarron
Executive VP of Finance13.9yrsUS$387.99k0.72% $81.6k
Samuel Barker
Independent Director5.4yrsUS$67.95k0.082% $9.3k
John Michael Banham
Non-Executive Director13.9yrsUS$69.37k0.091% $10.3k
David U'Prichard
Independent Chairman0yrsUS$100.28k0.096% $10.9k
Christopher Henney
Independent Vice Chairman0yrsUS$88.87k0.094% $10.7k
Edward Sikora
Member of Scientific Advisory Board0yrsno datano data
Michel Marty
Member of Scientific Advisory Board0yrsno datano data
Kenneth Harrap
Member of Scientific Advisory Board0yrsno datano data
Stanley Kaye
Member of Scientific Advisory Board0yrsno datano data

13.9yrs

Average Tenure

70yo

Average Age

Experienced Board: UXI3's board of directors are seasoned and experienced ( 13.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.2%.


Top Shareholders

Company Information

Cyclacel Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cyclacel Pharmaceuticals, Inc.
  • Ticker: UXI3
  • Exchange: DB
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$12.272m
  • Listing Market Cap: US$11.344m
  • Shares outstanding: 17.20m
  • Website: https://www.cyclacel.com

Number of Employees


Location

  • Cyclacel Pharmaceuticals, Inc.
  • 200 Connell Drive
  • Suite 1500
  • Berkeley Heights
  • New Jersey
  • 7922
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYCC.PNasdaqCM (Nasdaq Capital Market)PFD CONV EX 6%USUSDOct 2004
CYCCNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 2006
UXI3DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2006

Biography

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company’s oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 21:13
End of Day Share Price2020/02/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.